Publications by authors named "Lynne Ireland-Denny"
Article Synopsis
- Respiratory syncytial virus (RSV) is a major cause of severe lung infections globally, and developing an effective vaccine has been challenging, although recent advancements in vaccine technology bring hope for success.
- The new RSV vaccine V171 combines lipid nanoparticles and mRNA encoding an engineered version of the RSV F protein, which is designed to prompt robust immune responses within cells.
- Preclinical and Phase I trial results indicate that the mRNA vaccine is promising, and a new cell-based potency assay has been created to support its further clinical development by accurately measuring its effectiveness against a reference standard.
Previously reported pharmacological studies using the imidazole-containing histamine H3 receptor ligands GT-2331 (Cipralisant) and proxyfan resulted in a range of classifications (antagonist, agonist, and protean) for these compounds. We examined the role that the signaling system, with particular emphasis on the type of G protein, had on the pharmacology observed for H3 ligands. Ligands were assessed using assays measuring neurotransmitter release, cAMP, and guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTPgammaS) binding.
View Article and Find Full Text PDF